Skip to main content
SpringerLink
Log in

Imiquimod in superficial basal cell carcinoma: profile report

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Oldfield V, Keating GM, Perry CM. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 2005; 6(3): 195–200

    Article  PubMed  Google Scholar 

  2. Geisse J. Imiquimod: a viewpoint. Am J Clin Dermatol 2005; 6(3): 201

    Article  Google Scholar 

  3. Shumack S. Imiquimod: a viewpoint. Am J Clin Dermatol 2005; 6(3): 201

    Article  Google Scholar 

  4. Zeitouni N. Imiquimod: a viewpoint. Am J Clin Dermatol 2005; 6(3): 202

    Article  Google Scholar 

  5. Salasche S. Imiquimod 5% cream: a new treatment option for basal cell carcinoma. Int J Dermatol 2002 May; 41 Suppl. 1: 16–20

    Article  Google Scholar 

  6. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003 Oct 4; 327(7418): 794–8

    Article  PubMed  CAS  Google Scholar 

  7. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004 May; 50(5): 722–33

    Article  PubMed  Google Scholar 

  8. Gollnick H, Barona CG, Frank R, et al. Efficacy by clinical evaluation of imiquimod 5% cream in the treatment of superficial basal cell carcinoma: initial results from an ongoing, long-term follow-up study in Europe [abstract no. P480]. J Am Acad Dermatol 2004 Mar; 50(3 Suppl.): 124

    Article  Google Scholar 

  9. 3M Pharmaceuticals. Aldara (imiquimod): US prescribing information. St Paul (MN). 2004

  10. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002 Sep; 47: 390–8

    Article  PubMed  Google Scholar 

  11. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. The Australasian Multicentre Trial Group. J Am Acad Dermatol 2001 May; 44: 807–13

    Article  PubMed  CAS  Google Scholar 

  12. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002 Sep; 138: 1165–71

    Article  PubMed  CAS  Google Scholar 

  13. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000 Oct; 143(4): 843–5

    Article  PubMed  CAS  Google Scholar 

  14. Didona B, Benucci R, Amerio P, et al. Primary cutaneous CD30+ T cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004 Jun; 150(6): 1198–201

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imiquimod in superficial basal cell carcinoma: profile report. Drugs Ther. Perspect 22, 5–7 (2006). https://doi.org/10.2165/00042310-200622010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622010-00002

Search

Navigation